Skip to main content

Keratosis Pilaris

0
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AOBiome
AOBiomeMA - Cambridge
1 program
AO+MistN/A2 trials
Active Trials
NCT03268174Completed19Est. Feb 2017
NCT03243617Completed26Est. Sep 2016
Fitzpatrick Company
Fitzpatrick CompanyON - Waterloo
1 program
M22 IPLN/A1 trial
Active Trials
NCT05666011Unknown10Est. May 2023
Precision BioSciences
1 program
Salkera Emollient FoamPHASE_41 trial
Active Trials
NCT00944216Terminated1Est. Jan 2010

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Precision BioSciencesSalkera Emollient Foam
Fitzpatrick CompanyM22 IPL
AOBiomeAO+Mist
AOBiomeAO+Mist

Clinical Trials (4)

Total enrollment: 56 patients across 4 trials

NCT00944216Precision BioSciencesSalkera Emollient Foam

Efficacy and Safety of Salkera Emollient Foam in the Treatment of Moderate to Severe Keratosis Pilaris, a Prospective Study

Start: Jun 2009Est. completion: Jan 20101 patients
Phase 4Terminated

Laser to Aid in Treatment of Keratosis Pilaris on Arms

Start: Mar 2023Est. completion: May 202310 patients
N/AUnknown

Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.

Start: May 2016Est. completion: Feb 201719 patients
N/ACompleted

Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris

Start: Dec 2015Est. completion: Sep 201626 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.